Last reviewed · How we verify
Placebo I (Semaglutide)
Semaglutide is a GLP-1 receptor agonist that mimics glucagon-like peptide-1 to regulate blood glucose, reduce appetite, and promote weight loss.
Semaglutide is a GLP-1 receptor agonist that mimics glucagon-like peptide-1 to regulate blood glucose, reduce appetite, and promote weight loss. Used for Type 2 diabetes mellitus, Chronic weight management in adults with obesity or overweight with weight-related comorbidities, Cardiovascular risk reduction in patients with type 2 diabetes.
At a glance
| Generic name | Placebo I (Semaglutide) |
|---|---|
| Sponsor | Novo Nordisk A/S |
| Drug class | GLP-1 receptor agonist |
| Target | GLP-1R |
| Modality | Small molecule |
| Therapeutic area | Diabetes, Obesity, Cardiovascular |
| Phase | Phase 3 |
Mechanism of action
Semaglutide binds to and activates GLP-1 receptors on pancreatic beta cells, enhancing glucose-dependent insulin secretion and inhibiting glucagon release. It also acts on the central nervous system to reduce appetite and increase satiety, leading to decreased caloric intake and weight reduction. These combined effects improve glycemic control and cardiovascular outcomes in patients with type 2 diabetes and obesity.
Approved indications
- Type 2 diabetes mellitus
- Chronic weight management in adults with obesity or overweight with weight-related comorbidities
- Cardiovascular risk reduction in patients with type 2 diabetes
Common side effects
- Nausea
- Vomiting
- Diarrhea
- Constipation
- Abdominal pain
- Hypoglycemia (when combined with insulin or sulfonylureas)
- Pancreatitis (rare)
Key clinical trials
- A Clinical Study of Semaglutide Nasal Spray in Overweight or Obese Adults (PHASE1)
- A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Placebo in Children and Adolescents With Type 2 Diabetes (PHASE3)
- A Research Study to Look at How Well CagriSema Helps People Living With Obesity Lose Weight and Maintain Weight Loss in the Long-term (PHASE3)
- A Research Study to Investigate the Effects of CagriSema Compared to Placebo in People With Type 2 Diabetes and Painful Diabetic Peripheral Neuropathy (PHASE2)
- A Study to Measure the Effects of Using Tradipitant on Nausea and Vomiting After GLP-1R Agonist Use (PHASE2)
- A Clinical Trial to Evaluate The Effects of Semaglutide and Empagliflozin Combined to Automated Insulin Delivery on Diabetes Control in Adults Living With Type 1 Diabetes (PHASE3)
- The Safety, Tolerability, and Pharmacokinetics of of SYH9017 in Chinese Participants With Overweight and Obesity (PHASE1)
- Research Study Investigating How Well Semaglutide Works in People With Type 2 Diabetes Suffering From Overweight or Obesity (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Placebo I (Semaglutide) CI brief — competitive landscape report
- Placebo I (Semaglutide) updates RSS · CI watch RSS
- Novo Nordisk A/S portfolio CI